Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

Abstract

Much focus has been on the interaction of programmed cell death ligand 1 (PD-L1) on malignant B cells with programmed cell death 1 (PD-1) on effector T cells in inhibiting antilymphoma immunity. We sought to establish the contribution of natural killer (NK) cells and inhibitory CD163 monocytes/macrophages in Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL). Levels of PD-1 on NK cells were elevated in cHL relative to DLBCL. Notably, CD3CD56CD16 NK cells had substantially higher PD-1 expression relative to CD3CD56CD16 cells and were expanded in blood and tissue, more marked in patients with cHL than patients with DLBCL. There was also a raised population of PD-L1-expressing CD163 monocytes that was more marked in patients with cHL compared with patients with DLBCL. The phenotype of NK cells and monocytes reverted back to normal once therapy (ABVD [doxorubicin 25 mg/m, bleomycin 10 000 IU/m, vinblastine 6 mg/m, dacarbazine 375 mg/m, all given days 1 and 15, repeated every 28 days] or R-CHOP [rituximab 375 mg/m, cyclophosphamide 750 mg/m IV, doxorubicin 50 mg/m IV, vincristine 1.4 mg/m (2 mg maximum) IV, prednisone 100 mg/day by mouth days 1-5, pegfilgrastim 6 mg subcutaneously day 4, on a 14-day cycle]) had commenced. Tumor-associated macrophages (TAMs) expressed high levels of PD-L1/PD-L2 within diseased lymph nodes. Consistent with this, CD163/PD-L1/PD-L2 gene expression was also elevated in cHL relative to DLBCL tissues. An in vitro functional model of TAM-like monocytes suppressed activation of PD-1 NK cells, which was reversed by PD-1 blockade. In line with these findings, depletion of circulating monocytes from the blood of pretherapy patients with cHL and patients with DLBCL enhanced CD3CD56CD16 NK-cell activation. We describe a hitherto unrecognized immune evasion strategy mediated via skewing toward an exhausted PD-1-enriched CD3CD56CD16 NK-cell phenotype. In addition to direct inhibition of NK cells by the malignant B cell, suppression of NK cells can occur indirectly by PD-L1/PD-L2-expressing TAMs. The mechanism is more prominent in cHL than DLBCL, which may contribute to the clinical sensitivity of cHL to PD-1 blockade.

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

“…Although either B7-H1 or PD-1 could also interact with other proteins (B7-H1/B7–1, PD-1/PD-L2), the biological significance of these interactions in humans is not yet fully understood. While T cells are a primary target for suppression, as shown in the majority of studies, the PD pathway could also impair the functions of dendritic cells (Yao et al, 2009), macrophages (Yao et al, 2009), and NK cells (Benson et al, 2010; Huang et al, 2015; Vari et al, 2018). The PD-1 mediated suppression mechanisms appear to be complex, including apoptosis, induction of suppressive cytokines, anergy, exhaustion, and Treg induction (Chen and Han, 2015; Zou and Chen, 2008; Zou et al, 2016).…”

From the “missing self” hypothesis to adaptive NK cells: Insights of NK cell-mediated effector functions in immune surveillance

“…In NK cells, PD‐1 engagement can inhibit granule polarization, dampening NK cell function . PD‐1 is up‐regulated in the NK cell surface from patients with Kaposi sarcoma, multiple myeloma (MM), and lymphoproliferative disorders, suggesting that a high expression of PD‐1 is associated with NK cell dysfunction or immune suppression. In consequence, the use of mAb's anti‐PD‐1 can restore NK cell‐mediated antitumor activity .…”

Natural killer cells: From surface receptors to the cure of high‐risk leukemia (Ceppellini Lecture)

“…These cells, isolated from patients, did not kill PD‐L1 pos tumor cells, while cytotoxicity could be restored in the presence of mAbs disrupting the PD‐1/PD‐L1 interaction . PD‐1 pos NK cells were also found in patients with Kaposi sarcoma and Hodgkin lymphoma . Although, the molecular mechanism(s) involved in PD‐1 expression at the NK cell surface have not been identified yet, a pool of PD‐1 protein and mRNA has been identified in resting NK cells, suggesting the possibility of a prompt surface expression following appropriate stimulation .…”